Compare GT & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GT | AMLX |
|---|---|---|
| Founded | 1898 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2005 | 2021 |
| Metric | GT | AMLX |
|---|---|---|
| Price | $6.52 | $22.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $9.13 | ★ $21.56 |
| AVG Volume (30 Days) | ★ 8.3M | 1.9M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,280,000,000.00 | $380,786,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $5.43 | $7.61 |
| 52 Week High | $10.62 | $24.36 |
| Indicator | GT | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 46.45 | 76.43 |
| Support Level | $6.66 | $12.46 |
| Resistance Level | $6.78 | N/A |
| Average True Range (ATR) | 0.32 | 1.43 |
| MACD | -0.07 | 0.39 |
| Stochastic Oscillator | 25.93 | 97.69 |
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment. The company operates its business through three operating segments representing its regional tire businesses: Americas; Europe, the Middle East, and Africa (EMEA); and the Asia Pacific. The majority of its revenue is generated from the Americas business, which develops, manufactures, distributes, and sells tires and related products and services in North, Central, and South America, along with selling tires to various export markets, mainly through intersegment sales.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.